Company Overview
Snapshot
Founded in January 2023, Noxon operates with 1–10 employees. The company has secured funding across one round from one investor, NGT HealthCare II, to advance its drug development for fibrotic lung diseases.
Business overview
Noxon is a Health Tech & Life Sciences company focused on developing novel oral treatments for fibrotic lung diseases. Its core product, 3-CP (3-cabamoyl-proxyl), is a stable organic radical from the nitroxides group with unique antioxidant properties. This drug has demonstrated efficacy in reducing airway inflammation and hyper-responsiveness in animal models of allergic asthma, targeting the pharmaceutical and healthcare markets.
Log in to access full profile ›Company Intelligence Q&A
- When was Noxon founded?
- Noxon was founded in January 2023.
- What is Noxon's primary focus?
- Noxon focuses on developing a novel drug for the oral treatment of fibrotic lung diseases.
- What is 3-CP?
- 3-CP (3-cabamoyl-proxyl) is Noxon's product, a stable organic radical from the nitroxides group with unique antioxidant properties, designed to reduce airway inflammation and hyper-responsiveness.
- What is the current employee count at Noxon?
- Noxon currently has 1–10 employees.